PROSTATE CANCER CHEMOPREVENTION TRIAL

前列腺癌化学预防试验

• 批准号: 7605680
• 负责人: MAARTEN C BOSLAND
• 金额: $ 3.39万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605680
• 关键词: Characteristics; Chemoprevention; Chemopreventive Agent; Computer Retrieval of Information on Scientific Projects Database; Disease; Double-Blind Method; Failure; Frequencies; Funding; Grant; Institution; Malignant Neoplasms; Malignant neoplasm of prostate; Radical Prostatectomy; Randomized; Recurrence; Research; Research Personnel; Resources; Reverse Transcriptase Polymerase Chain Reaction; Risk; Source; Soy Proteins; United States National Institutes of Health; cancer cell; cancer recurrence; men

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this randomized, double-blind chemoprevention trial are to determine whether chemopreventive treatments with soy protein reduce or delay further rise in PSA in men that present with a PSA failure as the first sign of disease recurrence following radical prostatectomy for prostate cancer. A second objective is to determine whether chemopreventive treatment with soy protein delays prostate cancer recurrence following radical prostatectomy, as indicated by PSA failure in men who are at high risk for recurrrence because their cancers have unfavorable characteristics. The ability of soy protein to reduce the frequency of recurrence and the quantity of circulating prostate cancer cells detected by RT-PCR will be determined.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项随机，双盲化学预防试验的目标是确定用大豆蛋白质的化学预防治疗减少或延迟在PSA失败的男性中，PSA的进一步升高是PSA失败是前列腺癌的自由基前预切除术后疾病复发的第一个迹象。第二个目标是确定在前列腺切除术后的大豆蛋白质延迟前列腺癌的复发是否延迟，这是因为他们的癌症具有不利特征，因此患有高风险的男性PSA失败表明。将确定大豆蛋白减少复发频率和通过RT-PCR检测到的循环前列腺癌细胞量的能力。